Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pediatr Dermatol ; 29(6): 714-8, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23106672

RESUMEN

Atopic dermatitis (AD) can be extremely disabling and may cause psychological problems for affected children and their families. Moisturizers and emollients are important in the baseline daily skin care of patients with AD. To assess the effect of a 3-month, twice-daily treatment with an emollient on the quality of life (QoL) of parents with a child with mild to moderate AD (SCORing Atopic Dermatitis [SCORAD] ≤ 30, a multicenter open trial was performed by eight dermatologists on 191 volunteers. Evaluation by the dermatologist of the child's clinical condition (SCORAD) and of the efficacy and overall safety of the treatment was associated with a QoL questionnaire completed by one parent of the atopic child. A self-assessment of the global QoL and of the efficacy and overall safety was also performed. During the study, mean SCORAD dropped from 28 to 12 (p < 0.001), with good improvement in skin dryness and pruritus criteria. At the same time, the self-assessment of the global parent QoL scores dropped from 4.4 to 2.1 (p < 0.001) with 60%, 48% and 79% favorable parent opinions regarding wellbeing or improvement of the health condition, quality of sleep, and efficacy of the emollient, respectively. This trial revealed the efficacy of the product in improving parent QoL (85% of parents noted improvement in QoL), and its global safety was considered to be very good or good, with 80% favorable opinions in parents' declarative judgements and dermatologists' assessments. The emollient evaluated improves the course of AD and can improve the QoL of patients and their families.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/psicología , Emolientes/administración & dosificación , Salud de la Familia , Ácidos Oléicos/administración & dosificación , Aceites de Plantas/administración & dosificación , Calidad de Vida/psicología , Administración Tópica , Corticoesteroides/administración & dosificación , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Relaciones Padres-Hijo , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Resultado del Tratamiento
2.
Eur J Dermatol ; 21(1): 5-11, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21282088

RESUMEN

From time out of mind, man has grown hemp for both "industrial" and "recreational" use (it is then referred to as cannabis). Of course, cannabis has strong psychoactive properties and is one of the most commonly used "soft drugs" in the world. Clinicians should know the adverse effects on mucous membranes and on skin, which may sometimes entail an absolutely necessary stopping of consumption. Raynaud's phenomenon, as well as arteritis due to cannabis consumption may be extremely severe and result in worrying situations for both clinicians and patients.


Asunto(s)
Arteritis/clasificación , Cannabis , Fumar Marihuana , Arteritis/inducido químicamente , Arteritis/diagnóstico por imagen , Cannabis/efectos adversos , Cannabis/clasificación , Humanos , Fumar Marihuana/efectos adversos , Fumar Marihuana/fisiopatología , Membrana Mucosa/efectos de los fármacos , Fitoterapia , Piel/efectos de los fármacos , Ultrasonografía Doppler Dúplex
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA